Estée Lauder
No proof required
Up to $5,000
Claims opening soon
C
Celgene
A $34 million settlement resolves claims that Celgene engaged in price fixing to raise costs of cancer medications Thalomid and Revlimid.
ClosedUnited States-wideClaim status: Claim window closedPayout: Closed settlementNo longer claimable
About this settlement
The case involves claims of illegal price fixing by Celgene affecting cancer medication costs.
This settlement resolves allegations that Celgene engaged in a price fixing scheme to increase the cost of the cancer medications Thalomid and Revlimid. The court granted final approval on October 2, 2020.
Who qualifies
- Individuals who purchased Thalomid or Revlimid during the relevant period.
- Potential class members identified by the settlement administrator.
Closed settlement
Claim status: Claim window closed
Silk and Great Value
Proof required
Up to $300,000
96 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
746 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon